German Federal Joint Committee (G-BA)

On November 12, 2021, the Innovation Committee at the Federal Joint Committee (G-BA) has announced the selection of thirty project ideas for Innovation Funding of the new forms of care within the framework of the two-stage application process. A total of 123 project ideas were received, and only thirty were accepted.

In early-mid November 2021, the Federal Joint Committee (G-BA) has initiated an evaluation procedure for early benefit assessment for two new cardiovascular technologies (Revivent TC™ by BioVentrix and Trilogy™ Heart Valve System by JenaValve Technology) in heart failure, and aortic valve insufficiency and stenosis, respectively.

In late August 2021, the Innovation Committee at the Federal Joint Committee (G-BA) has announced funding of 52 innovative projects on health care research from the G-BA Innovation Fund.

On June 7, 2021, the Innovation Committee at the Federal Joint Committee (G-BA) has reported that 123 project ideas were received for Innovation Funding of the new forms of care within the new two-stage application process framework.

On May 6, 2021, the Federal Joint Committee (G-BA) announced the start of consultations about the design of three co-funded studies for cardiovascular methods in accordance with §137e SGB V.

The Innovation Committee at the Federal Joint Committee (G-BA) has launched the decisions database on its website.

On March 17, 2021, the Innovation Committee at the Federal Joint Committee (G-BA) published the determined funding priorities. Applicants are invited to submit ideas for projects that fall within one of these funding priorities. The deadline for submitting ideas is June 1, 2021.

On January 28, 2021, the Innovation Committee at the Federal Joint Committee (G-BA) published the first overview of the 28 innovative projects on new forms of medical care that will be funded. The projects concerning the technologies belonging to the cardiovascular, eHealth, orthopedic, neurology, nephrology, and other technology groups received funding.

In late December 2020, the Innovation Committee at the Federal Joint Committee (G-BA) has announced funding from the G-BA Innovation Fund of twenty-eight innovative projects on new forms of medical care.

On November 9, 2020, in accordance with §137h Paragraph 6 SGB V, the Federal Joint Committee (G-BA) has initiated an evaluation procedure for endovascular implantation of a stent-graft with valve element in tricuspid valve insufficiency within the framework of the early benefit assessment.

In mid-October 2020, the Federal Joint Committee (G-BA) has decided that three more biomarker-based tests in breast cancer will be covered by the statutory health insurance. Since January 2020, the "Oncotype DX Breast Recurrence Score" test is already reimbursed in Germany with a tariff of €3,296.50.

In late June 2020, the Innovation Committee at the Federal Joint Committee (G-BA) published funding priorities on its website. For the first time, the decision on the funding priorities was preceded by a consultation process. Healthcare stakeholders who are not members of the Innovation Committee were asked to come up with suggestions for funding topics and criteria.